SCARB1 and ischemia: In SHR however, HDL treatment in the presence of SR-BI blocking antibody did not result in any significant improvements in cardiac contractility, hemodynamics or ventricular pressure relative to ischemia or relative to the untreated controls (Figures 5A–F), suggesting the absolute requirement of SR-BI in HDL mediated cardiac protection in SHR.